Storia in 5 fonti

Celcuity gains FDA approval for closely watched breast cancer drug

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 g fa

Celcuity gains FDA approval for closely watched breast cancer drug

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

originale

morningstar.com1 g fa

Correction to Celcuity Gets FDA Approval Headline

Celcuity's breast cancer drug received approval from the Food and Drug Administration. "Clecuity Gets FDA Approval for Breast Cancer Drug," at 5:33 p.m. ET, misspelled the company name in the headline.

Leggi questa versione → originale

healio.com1 g fa

FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer

The FDA has approved a new targeted therapy combination for the most common subtype of breast cancer.Gedatolisib (Revtorpyk, Celcuity Inc.) plus fulvestrant, with or without palbociclib (Ibrance, Pfizer), was approved…

Leggi questa versione → originale

fiercepharma.com1 g fa

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big…

The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients with breast cancer.

Leggi questa versione → originale

ynetnews.com1 g fa

FDA approves breast cancer drug that cut progression risk by 76%

Revtorpyk was approved for women with advanced breast cancer whose disease worsened after previous hormone-based treatments; patients receiving the three-drug combination went a median 9.3 months without progression,…

Leggi questa versione → originale

Celcuity gains FDA approval for closely watched breast cancer drug

Confronto fonti

Celcuity gains FDA approval for closely watched breast cancer drug

Correction to Celcuity Gets FDA Approval Headline

FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big…

FDA approves breast cancer drug that cut progression risk by 76%

Timeline cronologica

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma

Correction to Celcuity Gets FDA Approval Headline

Celcuity gains FDA approval for closely watched breast cancer drug

FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer

FDA approves breast cancer drug that cut progression risk by 76%

Celcuity gains FDA approval for closely watched breast cancer drug

Confronto fonti

Celcuity gains FDA approval for closely watched breast cancer drug

Correction to Celcuity Gets FDA Approval Headline

FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big…

FDA approves breast cancer drug that cut progression risk by 76%

Timeline cronologica

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma

Correction to Celcuity Gets FDA Approval Headline

Celcuity gains FDA approval for closely watched breast cancer drug

FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer

FDA approves breast cancer drug that cut progression risk by 76%